Recent news on Ranexa

CV Therapeutics Significantly Reduces Operating Expenses  -  25 May 2007
PR Newswire (press release),..."Based on the results from the MERLIN TIMI-36 study and our historical Ranexa revenue trend, we believe that the difficult but necessary action we have

CV Therapeutics: 'High Chance' of Regadenoson Approval Sends ...  -  May 16, 2007
Seeking Alpha,Another feather in the company's hat is the growing sales of its chronic angina drug Ranexa that helped the company recently post a narrower first quarter

CV Therapeutics "buy," target price raised  -  Apr 25, 2007
newratings.comCV Therapeutics’ Ranexa sales grew 33% sequentially in the quarter, Cantor Fitzgerald adds. The analyst expects the company to continue to generate

CV Therapeutics "buy," target price raised  -  26 Apr 2007
newratings.comCV Therapeutics’ Ranexa sales grew 33% sequentially in the quarter, Cantor Fitzgerald adds. The analyst expects the company to continue to generate

Journal of the American Medical Association Publishes MERLIN TIMI ...  -  Apr 25, 2007
PharmaLive.com (press release),The Company plans to ask the US Food and Drug Administration (FDA) to modify the existing product labeling for Ranexa(R) (ranolazine extended-release

Use of CV Therapeutics' Ranexa to increase: survey  -  Apr 2, 2007
Therapeutics Daily (subscription) (press release),LOS ANGELES (Reuters) - Cardiologists appear poised to increase their use of CV Therapeutics Inc.'s angina drug Ranexa after a study released last week at a

CV Therapeutics' Ranexa trial could broaden use  -  Mar 27, 2007
Therapeutics Daily (subscription) (press release),The drug, Ranexa, was approved last year to treat chronic angina, chest pain caused by an insufficient supply of oxygen to the heart, in patients who have

Will CVT Bring In the Dough?  -  Apr 17, 2007
Motley FoolLast month, Rule Breakers pick CV Therapeutics (Nasdaq: CVTX) announced clinical trial results for its marketed angina drug Ranexa and presented data at the

CV Therapeutics to Announce 2007 First Quarter Financial Results ...  -  Apr 19, 2007
PharmaLive.com (press release),CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have

JACC Publishes Long-Term Safety and Tolerability Data from ...  -  Apr 6, 2007
Drug Newswire (press release),These data also suggest no evidence of increased mortality attributable to Ranexa based on two year survival rates of ROLE participants compared with

A Second Look: CV Therapeutics  -  Mar 28, 2007
Houston Chronicle,Shares hit a seven-year low on Monday ahead of Ranexa study results, but bounced back Tuesday. The stock has traded between $6.43 and $23.47 over the last

Biotech Day In Review: Regeneron Up On AMD Data  -  Mar 28, 2007
Seeking Alpha,On March 7, CV Therapeutics took a 24% hit after it announced that Ranexa did not meet its endpoints in a Phase III trial. The company was attempting to

CV Therapeutics Shares Reverse Course on Positive American College ...  -  Mar 27, 2007
Seeking Alpha,The analyst lowered her price target from $8 to $2 and in a note to clients, said that "as a result of Ranexa's diminished outlook we believe it may be

Broker Action For Wednesday, April 25  -  Apr 25, 2007
Forbes,Revenue jumped on sales of its chronic angina drug Ranexa. Downgrades are grounding shares of JetBlue (nasdaq: JBLU - news - people ).

Premarket Movers: Daktronics, NetLogic  -  Apr 9, 2007
Houston Chronicle,That includes expectations for Ranexa sales. Sales of the drug would likely accelerate in the hands of a larger company, which could also cut some sales and

Ahead of the Bell: CV Therapeutics  -  Mar 28, 2007
Forbes,The stock dropped to a seven-year low Monday as analysts anticipated bad news from clinical trials of its angina drug Ranexa. The Palo Alto, Calif.,

CV Therapeutics Shares Fall on Downgrade  -  Mar 28, 2007
International Business Times,Citigroup analyst Dr. Yaron Werber lowered the firm's price target to $6 from $15, stating that he saw diminished market potential for Ranexa,

Stocks to Watch, April 25: Apple, United Parcel Service, Amazon.com  -  Apr 24, 2007
FOX NewsCV Therapeutics Inc.'s (CVTX) first-quarter loss narrowed, on sales of its Ranexa drug, to $55.1 million, or 93 cents a share, from a year-earlier loss of

Wednesday's Health Winners & Losers  -  Mar 28, 2007
TheStreet.comCitigroup downgraded CV Therapeutics (CVTX - Cramer's Take - Stockpickr) based on diminished market potential for its angina drug Ranexa, high operating

Analyst downgrades 3-28-07: CV Therapeutics, Deutsche Telecom ...  -  Mar 28, 2007
Blogging StocksCitigroup cut CV Therapeutics Inc (NASDAQ: CVTX) to Sell from Hold with a $6 target due to the diminished market potential for Ranexa and its high operating

Medical News from the Business Pages  -  Apr 7, 2007
CounterPunch,Similarly, "Researchers said the angina drug ranolazine, marketed as Ranexa by CV Therapeutics, Inc., didn't show a benefit in reducing deaths and heart

Wednesday's Small-Cap Winners & Losers  -  Mar 28, 2007
TheStreet.com...rating to sell from hold, citing poor results from new-indication testing of its Ranexa drug, the complete results of which were publicized Tuesday.

Beazer, CV Therapeutics Slide  -  Mar 28, 2007
Wall Street Journal (subscription),...after Citigroup cut its rating on the stock to sell from hold, citing diminished market potential for angina drug Ranexa and high operating expenses.

Sector Snap: Biotech Stays Flat  -  Mar 27, 2007
Forbes,Shares of CV Therapeutics Inc. gained ground on mixed study results for its Ranexa, which is already approved to treat chronic angina.

CV Therapeutics Down on Predictions  -  27 Mar 2007
Forbes,Investors expect CV Therapeutics Inc. to report weak trial results for Ranexa, its angina treatment, and the biopharmaceutical company's stock fell to an

Analyst downgrades 3-26-07: Boston Scientific & Vonage downgraded ...  -  27 Mar 2007
Blogging StocksThe downgrade was ahead of the full Ranexa Merlin PIII data to be presented at the American College of Cardiology on Tuesday, March 27th,

On The Move For Monday, March 26  -  27 Mar 2007
Forbes,The biopharm recently released disappointing results for its heart-disease drug Ranexa. It’sa similar story at Boston Scientific (nyse: BSX - news - people

Stocks Come Under Pressure On Disappointing Housing Data - US ...  -  27 Mar 2007
Trading Markets,Deutsche Bank attributed the downgrade to expectations that the company will reveal disappointing trial results for its angina drug Ranexa.

Ranexa Won't Treat Heart Attacks, CV Therapeutics Falls 24%  -  Mar 8, 2007
Seeking Alpha,While CV Therapeutics' Ranexa or Ranolazine trials proved that there is no greater risk of arrhythmia or abnormal heart beats, it didn't prove Ranexa's

CV Therapeutics (CVTX) over all option implied volatility at 123 ...  -  Mar 7, 2007
StreetInsider.com (subscription),COWN says "Top-line results from the MERLIN trial reported established Ranexa's safety, but fell short of meeting the trial's primary efficacy endpoint in

JACC Publishes Long-Term Safety And Tolerability Data From ...  -  Mar 15, 2007
Medical News Today (press release),These data also suggest no evidence of increased mortality attributable to Ranexa based on two year survival rates of ROLE participants compared with

JACC Publishes Long-Term Safety and Tolerability Data from ...  -  Mar 14, 2007
PR-Inside.com (Pressemitteilung),The ROLE program evaluated 746 patients with chronic angina who chose to receive Ranexa(R) following their participation in the phase 3 Monotherapy

CV Therapeutics Feels the Pain  -  Mar 8, 2007
MSNBCCV Therapeutics' (CVTX) main drug, Ranexa, can only be used as a last-ditch treatment for coronary problems because of concerns that it might cause

High-Pressure Heart Drug  -  Feb 26, 2007
Forbes,Cardiologist Daniel C. Fisher has been trained by biotech CV Therapeutics to give speeches about its little-known heart drug Ranexa, and he believes the

CV Therapeutics Trial Results: Enough To Drive Profitability?  -  Mar 7, 2007
Seeking Alpha,A wider label should allow Ranexa to expand beyond niche status and potentially drive the company towards breakeven. However, given the current greater

A Good Failure?  -  Mar 6, 2007
Forbes,Ranexa is already FDA-approved to treat symptoms of angina, the crushing chest pain that results when clogged arteries prevent the heart from getting enough

CV Therapeutics shares plunge on study results  -  Mar 7, 2007
MarketWatchBOSTON (MarketWatch) -- CV Therapeutics Inc. shares plunged more than 20% Wednesday after the biopharmaceutical company said its angina drug Ranexa was

CV Therapeutics shares take a tumble on study results  -  Mar 8, 2007
Pharma Times (subscription),Shares in the USA's CV Therapeutics have plunged over 20% following the news that the firm's angina drug Ranexa was shown to be ineffective in treating

CV Therapeutics Announces Topline MERLIN TIMI-36 Results  -  Mar 7, 2007
Medical News Today (press release),Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or

A CV Therapeutics Buying Opportunity?  -  Mar 7, 2007
Motley FoolIn this large phase 3 study, Ranexa was being tested as a treatment for a group of heart ailments known as acute coronary syndromes (ACS).

Ahead of Bell: CV Therapeutics  -  Mar 7, 2007
Forbes,CV Therapeutics, based in Palo Alto, Calif., makes one drug, known as Ranexa. Ranexa is currently approved to treat chronic angina, but only in tandem with

CV heart therapy disappoints in trial  -  Mar 7, 2007
Pharmaceutical Business ReviewCV Therapeutics has said that an analysis of data from the study of its drug for angina, Ranexa, showed that the drug did not meet the primary efficacy

Why the CV Therapeutics Sell-off Was Overdone  -  Mar 9, 2007
Seeking Alpha,Jason Shade submits: Some CV Therapeutics (CVTX) investors could have been candidates for the company's angina treatment, Ranexa, following the company's

CV Therapeutics shares plunge on study results  -  Mar 7, 2007
MarketWatchBOSTON (MarketWatch) -- CV Therapeutics Inc. shares plunged more than 20% early Wednesday after the biopharmaceutical company said its angina drug Ranexa

CV Therapeutics shares plunge on study results  -  Mar 6, 2007
MarketWatchThere was no adverse death trend or arrhythmias in the study, which was designed to evaluate the efficacy and safety of Ranexa during acute and long-term

Deutsche Bank Downgrades CV Therapeutics (CVTX) to Hold  -  Mar 7, 2007
StreetInsider.com (subscription),Duetsche analyst says, "We are downgrading CVTX to Hold from Buy on Ranexa's failure to show clear efficacy as a first-line agent. Despite a safety profile

Market Report -- In Play (CVTX)  -  Mar 14, 2007
MSN MoneyThese data also suggest no evidence of increased mortality attributable to Ranexa based on two year survival rates of Role participants compared with

CV Therapeutics Shares Fall on Study  -  Mar 7, 2007
Forbes,Shares of CV Therapeutics Inc. plummeted Wednesday following mixed results from a late-stage study on its angina drug Ranexa, showing it met its safety goal

CV Therapeutics Shares Fall on Study  -  Mar 7, 2007
Houston Chronicle,NEW YORK — Shares of CV Therapeutics Inc. plummeted Wednesday following mixed results from a late-stage study on its angina drug Ranexa, showing it met its

UPDATE 2-CV angina drug not effective in ACS study  -  Mar 6, 2007
ReutersO: Quote, Profile , Research) said on Tuesday its angina drug Ranexa was not effective in a study of acute and long-term treatment of patients with a type

CV Therapeutics drug fails study  -  Mar 7, 2007
newratings.comNAS) Tuesday said its angina drug Ranexa was ineffective as a treatment for patients with a heart disease called acute coronary syndrome.

Stocks in the Spotlight Wednesday  -  Mar 7, 2007
Barron's (subscription)The biopharma's shares fell 24% to a seven-year low after reporting its late-stage angina drug Ranexa met safety standards but failed achieve an adequate

CV Therapeutics angina drug fails in new heart disease test  -  Mar 7, 2007
Bizjournals.com,CV Therapeutics Inc. said Tuesday its angina drug Ranexa failed in a test in patients with a type of heart disease. The Palo Alto company (NASDAQ: CVTX) saw

BUSINESS DIGEST  -  Mar 7, 2007
San Jose Mercury News,The drug, Ranexa, failed to show a statistically significant benefit in patients with heart attacks or unstable angina, the company said.

Volatility Persists in New York Trading  -  Mar 7, 2007
123Jump.com,CV Therapeutics Inc. (CVTX: chart) shares plummeted 25.3% following mixed results from a late-stage study on its angina drug Ranexa, showing it met

CV Therapeutics stock plunges after failed drug trial  -  Mar 7, 2007
Milwaukee Business Journal,Shares of CV Therapeutics Inc. plunged more than 25 percent Wednesday, a day after the company said that its angina drug Ranexa proved ineffective in a

UPDATE 1-CV angina drug not effective in ACS study  -  Mar 6, 2007
ReutersO: Quote, Profile, Research) said on Tuesday its angina drug Ranexa was not effective in a study of acute and long-term treatment of patients with a type of

CV Therapeutics angina drug not effective in study  -  Mar 6, 2007
ReutersNEW YORK, March 6 (Reuters) - CV Therapeutics Inc. said on Tuesday its angina drug Ranexa was not effective in a study of acute and long-term treatment of

CV Therapeutics angina drug not effective in study  -  Mar 6, 2007
ReutersCV Therapeutics said it believes the data could support expansion of Ranexa's approved uses to include the drug as a first choice treatment for angina.

CV Therapeutics Study Misses Endpoint  -  Mar 6, 2007
TheStreet.comCV Therapeutics said it believes the data could support expansion of the existing Ranexa (ranolazine extended-release tablets) indication to include first

CV Therapeutics dives as benchmarks slip  -  Mar 7, 2007
Therapeutics Daily (subscription) (press release),Late Tuesday, the drug developer said a clinical trial had shown Ranexa to be ineffective as an acute and long-term treatment for angina in patients with

CV Therapeutics stock plunges after failed drug trial  -  Mar 7, 2007
Washington Business Journal,Shares of CV Therapeutics Inc. plunged more than 25 percent Wednesday morning, a day after the company said that its angina drug Ranexa proved ineffective

CVT, We Wait for Thee  -  Feb 13, 2007
Motley FoolRule Breakers pick CV Therapeutics (Nasdaq: CVTX) has been dealing with just such a problem for its angina treatment, Ranexa, ever since the drug was

CV Therapeutics Reports 2006 Fourth Quarter and Full Year ...  -  Feb 9, 2007
PharmaLive.com (press release),For the quarter ended December 31, 2006, the Company recorded $9.0 million of net product sales for sales of Ranexa(R) (ranolazine extended-release tablets)

CV Therapeutics (CVTX) option implied volatility indicates Risk ...  -  Feb 20, 2007
StreetInsider.com (subscription),CV Therapeutics (Nasdaq: CVTX) : CVTX's MERLIN trail data results for Ranexa, a treatment for refractory angina, will .

Will MERLIN Work Magic For CV Therapeutics?  -  Feb 6, 2007
Seeking Alpha,A major reason for this precipitous drop can be attributed to the events surrounding CVTX’s most promising drug Ranexa which is used in the treatment of

UPDATE 2-CV Therapeutics 4th-quarter net loss narrows  -  Feb 8, 2007
ReutersO: Quote, Profile , Research) said on Thursday its fourth-quarter loss narrowed as sales increased for angina treatment Ranexa.

CV Therapeutics 4th-quarter net loss narrows  -  Feb 9, 2007
Therapeutics Daily (subscription) (press release),LOS ANGELES (Reuters) - CV Therapeutics Inc. said on Thursday its fourth-quarter loss narrowed as sales increased for angina treatment Ranexa.

CV Therapeutics 4Q Loss Narrows  -  Feb 8, 2007
Houston Chronicle,Biopharmaceutical company CV Therapeutics Inc. said Thursday its fourth-quarter loss narrowed on sales of angina treatment Ranexa.

Market Report -- In Play (CVTX)  -  Feb 9, 2007
MSN MoneyCo reported $9.0 mln of net product sales for sales of Ranexa, compared to $8.2 mln of net product sales recorded in the quarter ended Sept 30, 2006.

CV Therapeutics narrows Q4 loss  -  Feb 9, 2007
Bizjournals.com,CV Therapeutics' approved product, Ranexa, is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  -  Feb 21, 2007
PR Newswire (press release),CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have

MERLIN TIMI-36 Study Accepted As Late Breaking Clinical Trial at ...  -  Feb 7, 2007
PR Newswire (press release),Other accepted abstracts include: Ranexa(R) (ranolazine extended-release tablets) * Long-Term Therapy with Ranolazine Decreases mRNA and Protein Expression

Zacks Analyst Blog Highlights: CV Therapeutics, Telemig Celular ...  -  Feb 13, 2007
Business Wire (press release),Fourth quarter sales of Ranexa, launched in March 2006 for chronic angina, continue to move forward slowly. However, uptake will probably remain low until

CV Therapeutics to Announce 2006 Fourth Quarter and Year End ...  -  Jan 17, 2007
Earthtimes.orgCV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not

CVT Tries to Bring a Drug Overseas  -  Dec 26, 2006
Motley FoolCVT first attempted to get Ranexa approved in the EU to treat chronic angina back in early 2004. Unfortunately, the European Medicines Agency (Europe's

Dear Pharmacist: A look at some medications introduced in 2006  -  Dec 31, 2006
Therapeutics Daily (subscription) (press release),Ranexa(Rx, oral). New drug for chronic angina pain (chest pain) that hasn't responded to other medications. Amitiza(Rx, oral). This drug helps things move

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  -  Jan 4, 2007
PharmaLive.com (press release),CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not

CVT Tries to Bring a Drug Overseas  -  26 Dec 2006
Motley FoolCVT first attempted to get Ranexa approved in the EU to treat chronic angina back in early 2004. Unfortunately, the European Medicines Agency (Europe's

CV Therapeutics Files Application for European Marketing Approval ...  -  Dec 21, 2006
PipelineReview.com (press release),CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not

Zacks Analyst Blog Highlights: General Motors, CV Therapeutics ...  -  Dec 7, 2006
Business Wire (press release),Third quarter sales of Ranexa (launched in March for chronic angina) showed signs of improvement. However, uptake will probably remain low until the MERLIN

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional